IP Library Granted Patent US 8,802,438
Granted Patent B2
US 8,802,438 · App. 13/088,009 · Granted Aug 12, 2014

Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs

Inventors: Derrick Rossi (Roslindale, MA); Luigi Warren (Cambridge, MA)
Assignee: Children's Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,438
App. No.
13/088,009
Granted
Aug 12, 2014
Kind
B2
Abstract

Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Claims (14)

1. A composition for making induced pluripotent stem (iPS) cells comprising synthetic modified ribonucleic acids (RNAs) encoding OCT4, SOX 2, and KLF4, and cell growth medium, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic mRNAs is replaced with pseudouracil.

2. The composition of claim 1 , wherein the composition further comprises one or more synthetic modified RNAs encoding NANOG, c-MYC, and LIN28, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil.

3. The composition of claim 1 , wherein the composition permits an efficiency of reprogramming of at least 1%.

4. A kit comprising:

a. a vial comprising a synthetic modified RNA encoding an OCT4 reprogramming factor and a buffer;

b. a vial comprising a synthetic modified RNA encoding a SOX2 reprogramming factor and a buffer;

c. a vial comprising a synthetic modified RNA encoding a KLF4 reprogramming factor and a buffer; and

d. packaging and instructions therefor;

wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil.

5. The kit of claim 4 , further comprising a vial comprising a synthetic modified RNA encoding c-MYC and a buffer, a vial comprising a synthetic modified RNA encoding LIN28 and a buffer, or a combination thereof, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil.

6. The kit of claim 4 , further comprising a vial comprising a synthetic modified RNA molecule encoding a green fluorescent protein and a buffer, wherein each cytosine of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of the synthetic modified RNAs is replaced with pseudouracil.

7. The kit of claim 4 , wherein each vial contains a lipid or lipid-based molecule.

8. A method of reprogramming a somatic fibroblast cell into an induced pluripotent stem (iPS) cell, the method comprising contacting the somatic fibroblast cell with synthetic modified RNAs encoding the reprogramming factors OCT4, SOX 2, and KLF4 at least five consecutive times within 25 days, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil, thereby producing an induced pluripotent stem (iPS) cell.

9. The method of claim 8 , further comprising contacting the fibroblast somatic cell with a synthetic modified RNA encoding c-MYC, a synthetic modified RNA molecule encoding LIN28, or both, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil.

Assignments (4)
MERGER Recorded Dec 19, 2013
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 031823/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2013
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 031823/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2011
From: ROSSI, DERRICK
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 026257/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2011
From: WARREN, LUIGI
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 026258/0130 →
Continuity (3)
Provisional Application 61325003 · Apr 16, 2010
Provisional Application 61387220 · Sep 28, 2010
Related Publication 20120046346A1 · Feb 23, 2012